chronic graft-versus-host disease
Jakafi Approved To Treat Chronic GVHD in Adults and Children
The FDA approved ruxolitinib (Jakafi, Incyte) for chronic graft-versus-host disease after failure of one or two ...
OCTOBER 14, 2021
FDA Approves Rezurock to Treat Chronic Graft-Versus-Host Disease
The FDA approved belumosudil (Rezurock, Kadmon) for patients aged 12 years and older with chronic graft-versus-host ...
JULY 28, 2021
Ibrutinib Controls Chronic GVHD After Steroids Fail
San Diego—After allogeneic hematopoietic cell transplantation (allo-HCT), ibrutinib provides durable control ...
APRIL 27, 2017
Load more